Drugs / QAV680
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01103050 | Mar → Jul 2010 | allergic rhinitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01103037 | Mar → Sep 2010 | asthma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00814216 | Dec 2008 → Oct 2009 | asthma | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00784732 | Sep → Dec 2008 | seasonal allergic rhinitis | Novartis | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QAV680 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00784732 ↗ |
| Known as | NVP-QAV680 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2442750 ↗ |
| Known as | QAV690 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL2442750 ↗ |
| Action | Inhibit | “G protein-coupled receptor 44 antagonist” CHEMBL2442750 ↗1“CRTh2 Receptor Antagonist, QAV680” NCT00784732 ↗ |
| Modality | Small molecule | — CHEMBL2442750 ↗ |
| Route | Oral | “oral QAV680” NCT00814216 ↗ |
| Target | PTGDR2 | “G protein-coupled receptor 44 antagonist” CHEMBL2442750 ↗ |